• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Ranbaxy out to buy German, Romanian firms

      After taking a beating over the last few months, pharma major Ranbaxy Laboratories is out to radically alter its image.

      After the Atrovastin case loss against Pfizer, it's now on the prowl again.

      It is learnt that Ranbaxy Laboratories is likely to acquire two European companies " one is based in Germany and the other in Romania.

      The valuation of the German firm is in excess of $500 million while that of the Romanian firm is between $110 and $150 million, say sources.

      When contacted, a senior official of Ranbaxy Laboratories said that they were bound by confidentiality agreements and as such were not in a position to comment on the issue. Sources say that the acquisition is expected to be funded through a combination of cash and equity swapping.

      Sources close to the developments say that Ranbaxy has shown keen interest in a Germany-based pharma firm Betapharm.

      The company is currently owned by 3i, the leading European venture capitalist which backed a euro 300 million management buyout of Betapharm in March 2004.

      Germany has one of the highest levels of use for patent-free drugs in Europe, and this is scheduled to grow by 10 per cent over the next five years.

      Earlier, Ranbaxy had bid for the US-based generic pharma firm Alpharma and Ivax Corporation. Ranbaxy had also bid for Viatris GmbH & Co but lost out to a Swedish firm recently.

      Ranbaxy plans to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets.

      It also aspires to be among the top five generic players with sales of $5 billion by 2012. In order to achieve these objectives, the company is actively looking at inorganic growth, experts feel.

      In Romania, the company has shown interest for two pharma companies Terapia SA and Sindan.

      Terapia is a manufacturer of generics drugs in Romania, which clocked sales of $65 million in 2004 and EBIDTA of $20 million. A leading private equity firm " Advent International " which owns 91 per cent of Terapia, has appointed Merrill Lynch as the advisor to the deal.

      When contacted, the company spokesperson said that as a policy "we do not to comment on speculation. But we are certainly looking for inorganic growth in Europe and the US."

      Analysts feel that the acquisition in the European market would give generic penetration in Romania.

      The company received a major setback in the recent past when it lost cases in the US and UK.

      In fact, Ranbaxy has not won a patent challenge since August 2001 when it received approval from a United States' court for its version of GlaxoSmithKline Plc's Ceftin antibiotic.

      January 18, 2006


       

      Share this Article!

    Back to top^